ASHPOfficial

Seattle was one of the first cities in the U.S. to treat COVID-19 patients. Rena  Gosser, Clinical Ambulatory Care Manager at Harborview in Seattle, Washington shares lessons learned, clinical concerns, and plans for the safe reopening of some clinical services.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode is a recording of the ASHP COVID-19 Series (No CE) (Webinar)

Activity Date: May 8, 2020

NYU Langone's pharmacy teams were instrumental in the interprofessional response to the rapidly changing demands in the care of COVID-19 patients. Navigating the evidence-based medicine and emerging evidence was a key aspect of the pharmacy team’s role and is the focus of this podcast.  If you would like to learn more about how clinical leaders from NYU Langone kept pharmacists engaged at the bedside and positively impacted the organization, please see the full webinar recording at ASHP elearning.org.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Today on ASHPOfficial, we chat with student leaders across the nation about their perspectives on the COVID-19 pandemic. In this podcast, we will dive into how students are adapting to the virtual learning model and how student societies are coping with the changing environment. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

We chat with Dr. Lisa Deal, Director of Pharmacy, Sun Behavioral Health Delaware in Georgetown, Delaware, about the unique aspects of managing mental health disorders during the COVID-19 pandemic. Considerations for both patient and clinician mental health will also be discussed.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Today on ASHPOfficial, we chat with student leaders across the nation about their perspectives on the COVID-19 pandemic. In this podcast, we will dive into how students are adapting to the virtual learning model and how student societies are coping with the changing environment.  

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

 

Remdesivir has been added to the FDA Emergency Use Authorization list for the treatment of hospitalized patients with severe COVID-19 disease. As such, pharmacists may have questions about the practical and operational aspects of the procurement and utilization of this medication.  This podcast focuses on investigational drug services, dose conservation, and clinical experiences with remdesivir.  In order to learn more about early information on the clinical use of and access to Remdesivir for the treatment of patients with COVID-19, please see the full webinar recording at ASHP elearning.org.

*Recorded on 5/13

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Jillanne Schulte Wall, ASHP Senior Director, Health & Regulatory Policy and Mary Ann Kliethermes, ASHP Director, Medication Safety & Quality, discuss CMS’s recent telehealth changes, the resulting regulatory flexibilities that are helpful to our members and their patients, and ASHP’s next steps on telehealth advocacy.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

ASHP sits down with Dr. Jill Starykowicz, PharmD, BCCCP, Clinical Pharmacy Specialist, Medical/ Cardiac Intensive Care Unit and Director, PGY2 Critical Care Pharmacy Residency at Advocate Lutheran General Hospital in Park Ridge, Illinois as she discusses cytokine storm in critically ill COVID-19 patients. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician

 

We chat with Michael Gulseth about the unique aspects of treating COVID-19 patients that present with coagulopathies. Assessing risk of thromboembolism and anticoagulation strategies in these patients will also be discussed.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Anticoagulants are moving to the frontline in some patients with COVID-19 as emerging data shows pro-thrombotic complications occurring. Many of these agents are weight based and require lab monitoring for efficacy and safety. Unfortunately, obesity is an ongoing epidemic in the US as well and potentially worse outcomes in those with COVID-19. It is imperative that pharmacists have an understanding on how the pharmacokinetics can be altered in patients that are obese or large body weight, along with the recommended dosing weight to use.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.